Chlorthalidone vs Hydrochlorothiazide and Kidney Outcomes in Patients With Hypertension
Open Access
- 2 December 2024
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (12) , e2449576
Abstract
Importance: Hypertension is a risk factor for the development and progression of chronic kidney disease (CKD). It is unclear whether different thiazide diuretics have a differential impact on kidney outcomes.Objective: To compare kidney outcomes in patients with hypertension taking chlorthalidone and hydrochlorothiazide.Design, Setting, and Participants: This prespecified secondary analysis of the Diuretic Comparison Project, a randomized clinical trial comparing chlorthalidone and hydrochlorothiazide for the treatment of hypertension, was conducted between June 1, 2016, and June 1, 2022, through Veterans Affairs facilities nationwide. This analysis extended follow-up to December 31, 2023. Veterans 65 years or older with hypertension who were taking hydrochlorothiazide were included.Intervention: The Diuretic Comparison Project randomized 13 523 participants to continue hydrochlorothiazide or switch to chlorthalidone.Main Outcome and Measures: The main kidney outcome was CKD progression, defined as doubling of serum creatinine level from baseline, a terminal estimated glomerular filtration rate (eGFR) less than 15 mL/min, or dialysis initiation.Results: Analysis included 12 265 participants (90.7%) with a baseline and 1 or more follow-up creatinine measurements (median [IQR] age, 71 [69-75] years; 3.2% female and 96.8% male). The mean (SD) study duration was 3.9 (1.3) years. Chlorthalidone was not superior to hydrochlorothiazide at preventing kidney outcomes (369 of 6118 [6.0%] vs 396 of 6147 [6.4%]; hazard ratio [HR], 0.94; 95% CI, 0.81-1.08; P = .37). Similar results were observed when a 40% or greater reduction of eGFR was substituted for doubling of creatinine in the above outcome, as well as any of the components of the primary composite outcome. There was no difference in the incidence of CKD (961 of 4520 [21.3%] for chlorthalidone vs 939 of 4518 [20.8%] for hydrochlorothiazide; P = .59) or acute kidney injury requiring hospitalization (391 [6.4%] for chlorthalidone vs 379 [6.2%] for hydrochlorothiazide; P = .63) between groups. However, a statistically significant increased incidence of hypokalemia for chlorthalidone vs hydrochlorothiazide was observed (545 [8.9%] vs 426 [6.9%]; P < .001).Conclusions and Relevance: Chlorthalidone was not superior to hydrochlorothiazide for kidney outcomes but was associated with an increased risk for hypokalemia. Given these findings, clinicians should feel confident using either agent for the treatment of hypertension and kidney outcomes.Trial Registration: ClinicalTrials.gov Identifier: NCT02185417Keywords
This publication has 25 references indexed in Scilit:
- Chlorthalidone Versus Hydrochlorothiazide for the Treatment of Hypertension in Older AdultsAnnals of Internal Medicine, 2013
- Long-Term Renal and Cardiovascular Outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants by Baseline Estimated GFRClinical Journal of the American Society of Nephrology, 2012
- Associations of Proteinuria, Fluid Volume Imbalance, and Body Mass Index with Circadian Ambulatory Blood Pressure in Chronic Kidney Disease PatientsKidney and Blood Pressure Research, 2012
- CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trialsBMJ, 2010
- Cardiovascular Outcomes in High-Risk Hypertensive Patients Stratified by Baseline Glomerular Filtration RateAnnals of Internal Medicine, 2006
- Is Population-Wide Diuretic Use Directly Associated With the Incidence of End-Stage Renal Disease in the United States?A HypothesisAmerican Journal of Hypertension, 2005
- Renal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a DiureticArchives of internal medicine (1960), 2005
- A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertensionNephrology Dialysis Transplantation, 2004
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.1991